GHB

GHB's onset is fast -- effects typically emerge within 15 to 30 minutes of swallowing a dose on an empty stomach, sometimes sooner. The first sign is usually a spreading warmth through the chest and limbs, as if someone slowly turned up an internal thermostat. Tension in the shoulders and jaw dissolves. There is a gentle uplift in mood that feels organic rather than forced, like the moment a good conversation clicks and you stop being self-conscious. Users frequently describe the initial come-up as the best version of having two or three drinks -- the looseness and sociability of alcohol, but without the mental dullness or physical heaviness.

At low to moderate doses, the experience settles into a distinctive state that is hard to compare directly to any other drug. The body feels light and fluid, movement becomes pleasurable, and there is a tactile richness to physical contact that users consistently highlight. Music sounds warmer and more emotionally resonant. Conversations flow easily, and there is often a genuine increase in empathy and emotional openness that draws comparisons to MDMA, though it is subtler and less "pushy" -- more of a natural warmth than an overwhelming wave of love. Sexual arousal and sensitivity frequently increase, which is one of the primary reasons GHB has become embedded in chemsex culture. The mental state remains surprisingly clear relative to the degree of physical relaxation and disinhibition, which is perhaps the single characteristic users cite most often as distinguishing GHB from alcohol.

The experience has a quality of physical bliss that is difficult to articulate. Reddit users describe it as "your body feeling like it's getting a hug from the inside," or "the physical contentment of lying in a warm bath but while being fully functional and social." There is often a subtle dizziness or lightheadedness, especially when standing up quickly, and coordination is mildly impaired -- enough that dancing feels great but driving would be catastrophically dangerous.

Here is where the experience becomes treacherous. The dose-response curve of GHB is not a gentle slope -- it is a cliff edge. The distance between "this feels incredible" and "unconscious on the floor" can be as little as half a milliliter of liquid, and this transition happens not gradually but abruptly. Consciousness does not fade like it does with alcohol; it switches off. One moment a person is talking and laughing, and the next they are collapsed in a deep, unrousable sleep. Bystanders frequently describe this as terrifying to witness -- there is no warning phase of slurred speech and drowsiness that gives people time to react. This abrupt threshold is the pharmacological reality that makes GHB categorically more dangerous than alcohol at the level of subjective experience, regardless of how pleasant the lower-dose effects feel.

The duration is short -- typically 1.5 to 3 hours -- and the comedown is remarkably clean. Most people feel essentially back to baseline within 4-5 hours, often with a sense of refreshment rather than the depleted feeling left by stimulants or the grogginess of other depressants. This clean offset, however, is a double-edged sword: it invites redosing, and redosing is where the dose-response cliff claims most of its victims, as residual GHB in the bloodstream stacks with the new dose in ways that are difficult to predict.

GHB operates through two distinct receptor systems in the central nervous system, and this dual mechanism explains its paradoxical mix of stimulating and sedating effects.

The GHB Receptor

At lower concentrations -- closer to endogenous brain levels -- GHB primarily activates its own dedicated receptor, a G-protein coupled receptor found in discrete brain regions including the hippocampus, cortex, and striatum. This receptor is excitatory: its activation triggers glutamate release and stimulates dopamine release in the mesolimbic pathway, producing the euphoria, sociability, and stimulant-like effects at low recreational doses. The GHB receptor's full physiological role remains incompletely understood, but it appears to function as a neuromodulator involved in sleep-wake regulation and memory processing.

GABA-B Receptor Agonism

At higher concentrations -- the range reached at recreational and supratherapeutic doses -- GHB acts as a weak but clinically significant agonist at GABA-B receptors, the same inhibitory system targeted by baclofen. GABA-B activation is responsible for GHB's sedative, muscle-relaxant, anxiolytic, and anesthetic effects. The sedative properties are blocked by GABA-B antagonists like CGP-35348, confirming this receptor mediates the "downer" side of the experience. GABA-B activation also inhibits dopamine release, creating a biphasic dopamine pattern: low doses increase dopamine (via GHB receptor), high doses suppress it (via GABA-B), then release it again as concentrations fall.

The Biphasic Dopamine Effect and the "Rebound"

This biphasic mechanism explains the rebound awakening. Users who take GHB as a sleep aid often report falling into deep sleep for 3-4 hours and then waking abruptly, feeling alert and refreshed. As GHB is metabolized and blood levels drop, concentrations fall below the GABA-B threshold while still engaging the excitatory GHB receptor, producing a burst of wakefulness and dopamine-driven alertness.

Serotonin and Tryptophan

GHB increases tryptophan transport across the blood-brain barrier, boosting substrate availability for serotonin synthesis. This serotonergic component likely contributes to the mood elevation, empathogenic warmth, and sleep-regulating effects at moderate doses. The interplay between enhanced serotonin, biphasic dopamine, and GABA-B inhibition creates GHB's characteristic pharmacological fingerprint -- a substance that feels simultaneously relaxing and euphoric in a way no other single drug replicates.

Metabolism and Duration

GHB is rapidly absorbed orally (peak plasma in 20-45 minutes) and metabolized via GHB dehydrogenase to succinic semialdehyde, entering the Krebs cycle as succinate -- ultimately broken down into CO2 and water with zero-order kinetics at higher doses. Its elimination half-life is only 30-50 minutes, producing a total duration of 1.5-3 hours. This rapid clearance is both a feature (short effects, minimal hangover) and a liability (the short half-life drives compulsive redosing and the around-the-clock dosing pattern that defines GHB addiction).

GHB was first synthesized in 1874 by Russian chemist Alexander Zaytsev, though its pharmacological properties went unexplored for nearly a century. The substance entered medical science in the early 1960s when French researcher Henri Laborit began investigating it as a tool for studying GABA neurotransmission, since unlike GABA itself, GHB could cross the blood-brain barrier. Laborit discovered that it possessed sedative, anesthetic, and muscle-relaxant properties, and by 1964 GHB was being used as an intravenous anesthetic agent in European hospitals, particularly in France and Italy, including as an adjunct during childbirth.

Through the 1970s and 1980s, GHB found niche medical applications as a narcolepsy treatment and an experimental therapy for alcohol dependence. In the late 1980s, it gained a following in the American bodybuilding community after studies suggested it stimulated growth hormone release during sleep. It was sold freely as a dietary supplement in health food stores until the FDA banned over-the-counter sales in 1990 following reports of adverse reactions.

The 1990s brought GHB into club and rave culture, where its euphoric and disinhibiting effects made it popular alongside MDMA and ketamine. This era also brought its darkest association: media coverage increasingly linked GHB to drug-facilitated sexual assault, owing to its ability to cause rapid unconsciousness and amnesia when slipped into drinks. In March 2000, the United States placed GHB on Schedule I of the Controlled Substances Act. Yet in 2002, the FDA simultaneously approved sodium oxybate (brand name Xyrem) as a Schedule III prescription treatment for narcolepsy with cataplexy -- creating the unusual legal situation of the same molecule existing in two different schedules depending on its context of use. In 2020, Jazz Pharmaceuticals introduced Xywav, a lower-sodium reformulation.

Today, GHB occupies a smaller corner of the recreational drug landscape than substances like MDMA or ketamine, partly due to its reputation for danger and partly because sourcing pharmaceutical-grade material is difficult. Its user community tends to be well-informed about dosing risks, though even experienced users report alarming close calls that underscore the substance's unforgiving pharmacology.